RxDoctor Payments Data

Jeremy Schenkein, MD

Pulmonary Disease · Mechanicsville, VANPI 1851319180

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $98,672 of the $114,014 with a category attached, or 86.5%. GSK accounts for 88.5% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2023 at $24,809 and has fallen 84.4% since, to $3,860 in 2025. Among pulmonary disease clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$114,014in general payments, 2019–2025

Across 637 payments — averaging $178.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$101K
  • AstraZeneca$2K
  • Viiv Healthcare Company$2K
  • Intuitive Surgical$1K
  • Mylan Specialty L.p.$1K
  • Medical Device Business Services, Inc.$975
  • plus $6K from 33 others

What the payments were for

  • Speaking & faculty fees$98,67287%
  • Travel & lodging$2,8673%
  • Food & beverage$12,23811%
  • Education$2370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$114,014 in reported general payments places this provider in the 95th percentile of 317 pulmonary disease providers in Virginia.

See all pulmonary disease providers in Virginia

Medicare billing

Part B allowed, 2024
$693,993
Medicare patients
712
Services billed
13,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter855$680,500
Breztri AerosphereBudesonide/Glycopyr/Formoterol213$179,443
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr337$167,015
OfevNintedanib Esylate12$159,825
Breo ElliptaFluticasone/Vilanterol297$140,755
Stiolto RespimatTiotropium Br/Olodaterol Hcl151$104,435
Spiriva RespimatTiotropium Bromide127$79,571
SymbicortBudesonide/Formoterol Fumarate112$39,754
Spiriva HandihalerTiotropium Bromide29$28,570
Fluticasone-SalmeterolFluticasone Propion/Salmeterol144$22,129
Albuterol Sulfate HfaAlbuterol Sulfate750$18,152
Wixela InhubFluticasone Propion/Salmeterol145$14,387
EliquisApixaban21$12,144
Incruse ElliptaUmeclidinium Bromide33$11,588
Arnuity ElliptaFluticasone Furoate41$10,265

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$100,847$1,010,1221,563 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$846$352,322306 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$1,825$226,131337 claims
PfizerEliquis$220$12,14421 claims
MerckDulera$19$5,72212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 317 pulmonary disease providers in Virginia.

Other pulmonary disease in Mechanicsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →